99mTc-Sestamibi SPECT/CT Evaluation of Renal Oncocytomas
Clinical Nuclear Medicine Open · 2024
DOI: 10.1097/nm9.0000000000000008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Nuclear Medicine Open, 2024. Verfasst von Nadia Nelson und 2 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
We present 2 cases of the benign renal neoplasm, oncocytoma, evaluated with 99m Tc-sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) imaging. Oncocytoma is a benign, solid enhancing renal mass that resembles the much more common renal cell carcinoma on standard imaging studies. Differentiation can be difficult due to shared imaging and histological characteristics; therefore, diagnosis historically primarily relied on resection. However, in a subset of patients who are poor candidates for surgical excision or percutaneous biopsy, a possible option for planning follow-up management is 99m Tc-sestamibi SPECT/CT imaging. These cases highlight the role of 99m Tc-sestamibi SPECT/CT imaging in differentiating benign oncocytomas from malignant renal cell carcinomas.
Zitieren
APA
Nelson, N., Eichhorn, J., & Manzil, F. F. P. (2024). 99mTc-Sestamibi SPECT/CT Evaluation of Renal Oncocytomas. Clinical Nuclear Medicine Open. https://doi.org/10.1097/nm9.0000000000000008
Vancouver
Nelson N, Eichhorn J, Manzil FFP. 99mTc-Sestamibi SPECT/CT Evaluation of Renal Oncocytomas. Clinical Nuclear Medicine Open. 2024. doi:10.1097/nm9.0000000000000008
BibTeX
@article{Nelson2024,
author = {Nelson, Nadia and Eichhorn, Joshua and Manzil, Fathima Fijula Palot},
title = {99mTc-Sestamibi SPECT/CT Evaluation of Renal Oncocytomas},
journal = {Clinical Nuclear Medicine Open},
year = {2024},
doi = {10.1097/nm9.0000000000000008}
}
EUVIMED